98%
921
2 minutes
20
The discriminative performance of biomarkers often changes over time and exhibits heterogeneity across subgroups defined by patient characteristics. Assessing how this performance varies with these factors is crucial for a comprehensive evaluation of biomarkers and to identify areas for improvement in sub-populations with poor performance. Additionally, the presence of competing risks complicates the assessment of discriminative performance. Ignoring competing risks can lead to misleading conclusions, as the biomarker's performance for the event of interest, such as disease onset, may be confounded by its performance for competing events, such as death. To address these challenges, we develop a regression model to assess the impact of covariates on the discriminative performance of biomarkers, characterized by the covariate-specific time-dependent Area-undercurve (AUC) for a specific cause. We construct a pseudo partial-likelihood for estimation and inference and establish the asymptotic properties of the proposed estimators. Through simulation studies, we demonstrate the finite sample performance of these estimators, and we apply the proposed method to data from the African American Study of Kidney Disease and Hypertension (AASK).
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12366773 | PMC |
http://dx.doi.org/10.1007/s12561-025-09499-0 | DOI Listing |
Eur J Clin Microbiol Infect Dis
September 2025
Department of Infectious and Tropical Diseases, Toulouse University Hospital, Toulouse, 31059 Cedex 9, France.
Purpose: This narrative review aims to provide an overview of current knowledge on mpox, emphasizing updated epidemiology and recent advances in treatment and prevention strategies, in light of the latest outbreaks.
Methods: We searched PubMed and Google Scholar for publications on 'Mpox' and 'Monkeypox' up to June 5, 2025. Grey literature from governmental and health agencies was also accessed for outbreak reports and guidelines where published evidence was unavailable.
Curr Atheroscler Rep
September 2025
Division of Gastroenterology and Hepatology, Lynda K. and David M. Underwood Center for Digestive Health, Houston Methodist Hospital, Houston, TX, USA.
Purpose Of Review: This review aims to characterize the known cardiovascular (CV) manifestations associated with inflammatory bowel disease (IBD) and the underlying mechanisms driving these associations.
Recent Findings: Gut dysbiosis, a hallmark of patients with IBD, can result in both local and systemic inflammation, thereby potentially increasing the risk of cardiovascular disease (CVD) in the IBD population. Micronutrient deficiencies, anemia, and sarcopenia independently increase the risk of CVD and are frequent comorbidities of patients with IBD.
High Blood Press Cardiovasc Prev
September 2025
Department of Cardiology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Blood pressure variability (BPV), independent of mean BP, is an emerging predictor of cardiovascular risk and hypertension-mediated organ damage. However, its clinical utility remains limited due to the lack of clear guideline recommendations, leading to variability in physician practices. Using the modified Delphi method, this is the first Egyptian consensus to provide expert recommendations for integrating BPV in Egypt's resource-limited settings.
View Article and Find Full Text PDFEndocrine
September 2025
Otorhinolaryngology, Head and Neck Surgery, Candiolo Cancer Institute, FPO-IRCCS Turin, Turin, Italy.
Background: While osteoporosis in primary hyperparathyroidism (PHPT) is widely studied, PHPT patients with osteopenia remain less characterized. This study aimed to evaluate the prevalence, biochemical features, and estimated fracture risk of osteopenic PHPT patients in a real-life cohort.
Methods: We retrospectively analyzed a consecutive series of PHPT patients with available densitometric data at three sites.
Ann Hematol
September 2025
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Approximately 30-40% of diffuse large B-cell lymphoma (DLBCL) patients will develop relapse/refractory disease, who may benefit from novel therapies, such as CAR-T cell therapy. Thus, accurate identification of individuals at high risk of early chemoimmunotherapy failure (ECF) is crucial. Methods.
View Article and Find Full Text PDF